Cosmo Bio (TYO: 3386)

The 3Q cumulative total was in line with the plan despite an increase in revenue and a decrease in profit. We would like to see the progress of strategic measures confirmed in the full-year results.

♦ 3Q FY12/2024 Financial Highlights

Cosmo Bio's 3Q FY12/2024 results, announced on November 7,2024, showed an increase in revenue but a decrease in profit but were generally in line with forecasts. On a cumulative basis, sales were 7.4 billion yen (+7% YoY), operating profit was 360 million yen (-17% YoY), and ordinary profit was 380 million yen (-30% YoY). Quarterly profit attributable to owner of parent was 290 million yen (-20% YoY).

Sales growth has accelerated since the 2Q, and the performance now exceeds the company's expectations. Both research reagents and equipment have seen sales increase by 7%. Sales are progressing smoothly with university and corporate customers, and business with bioventures is also picking up.

However, the dollar-yen exchange rate fell to 150 yen per dollar on a cumulative basis (a depreciation of 12 yen YoY), and the gross profit margin fell 2.4 percentage points to 33.4% on a cumulative basis. Meanwhile, the company increased personnel expenses and other costs as expected, resulting in declining profits.

♦ FY12/2024 full-year earnings forecast unchanged

The company has again left its full-year earnings forecast unchanged. The forecast for the second half of the year is 150 yen to the dollar, sales of 9.8 billion yen (+4% YoY), operating profit of 390 million yen (-25% YoY), ordinary profit of 450 million yen (-31% YoY), and net profit attributable to owner of parent of 310 million yen (-30% YoY).

The current market rate for the dollar-yen exchange rate is weaker than the assumed rate, so caution is needed. However, the company believes that there is no need to change its initial plan, as the results up to the 3Q have progressed as expected, and it is also feeling a response to the increasing revenue trend.

♦ Stock Price Trends and Points to Watch

The company announced its 2Q results on August 5, 2024, when the stock market was in a sharp decline, and announced a full-year dividend increase and a share buyback 'to achieve management conscious of capital costs and stock prices.' The company's share price has since performed strongly, outperforming the TOPIX. The yen has weakened since October, but the company's share price has had no negative impact.

The main reasons for this are that, in addition to the fact that sales have been strong and profits are on track to meet expectations, there is little concern about a fall in valuations (although the 22x forecast PER is no longer considered undervalued), with a PBR of 0.77x and a forecast dividend yield of 4.25% (3.07% for the year-end dividend alone). Furthermore, the company has repurchased 95,200 shares worth approximately 100 million yen in total by the end of October, and it is expected to buy back approximately 200 million yen worth of shares by July 31, 2025. In addition, the company has set out a medium-term plan for improving its performance and ROE, with the aim of 'to achieve management conscious of capital costs and stock prices'.

The next point to watch, on top of the dollar to yen rate, is whether the full-year results for FY12/2024 will be in line with expectations, whether the full-year earnings forecast for FY12/2025 will show an increase in profits, whether shareholder returns will be maintained or increased, and what progress will be shown in strategic measures that will lead to medium-term earnings growth and the achievement of an ROE of 8%.

In particular, we are looking forward to seeing the globalization of the trading company business through the use of IT (we expect to see an increase in profits and a reduction in foreign exchange risk through the strengthening of exports), the launch of Scientist³, a matching site for commissioned services, and the visualization of the potential of the Chicken egg bioreactor business.

3Q results update

Pharmaceuticals and pharmaceutical wholesalers

As of December 12, 2024

Share price (12/11)	1,153 Yen
52weeks high/low	¥1,150/1,160
Avg Vol (3 month)	6.0 thou shrs
Market Cap	¥6.97 bn
Enterprise Value	¥3.47 bn
PER (24/12 CE)	21.7 X
PBR (23/12 act)	0.8 X
Dividend Yield (24/12)	4.3 %
ROE (23/12)	5.4 %
Operating margin (23/12)	5.6%
Beta (5Y Monthly)	0.3
Shares Outstanding	6.048 mn shrs
Listed market	TSE Standard

Share price performance



Points of interest

In the short term, the focus is on the dollar-yen exchange rate, which determines import costs. In the medium to long term, the focus is on the globalization of trading company functions, which aims to expand business while mitigating foreign exchange risk, Scientist³, a commissioned service matching service, and developing value-added businesses such as the Chicken egg bioreactor business.

This report (financial update) has been prepared at the request of Cosmo Bio. For details, please refer to the Disclaimer on the last page.

Company profile

Cosmo Bio Co., Ltd. is a trading company specializing in biotechnology with the objective of 'contributing to the advancement of life science'. It is one of the leading providers of life science research reagents, offering as many as 12 million items from approximately 500 manufacturers worldwide. In recent years, it has expanded its trading company functions globally and entered into contract services and proprietary manufacturing and sales business. Expectations are high for this contribution to earnings, improved capital efficiency and higher PBR.

Key financial data

Unit: million yen	2019/12	2020/12	2021/12	2022/12	2023/12	2024/12 CE	
Sales	7,590	8,092	9,231	9,553	9,340	9,800	
EBIT (Operating Income)	406	753	1,050	817	521	390	
Pretax Income	388	1,008	1,099	790	653	450	
Net Profit Attributable to Owner of Parent	237	674	737	517	442	310	
Cash & Short-Term Investments	2,516	3,259	3,555	3,036	3,025		
Total assets	8,890	9,640	10,072	10,313	10,872		
Total Debt	25	25	25	25	25		
Net Debt	-3,000	-3,000	-3,000	-3,000	-3,000		
Total liabilities	1,566	1,776	1,750	1,693	1,844		
Total Shareholders' Equity	8,445	8,445	8,445	8,445	8,445		
Net Operating Cash Flow	569	803	648	306	744		
Capital Expenditure	120	120	120	120	120		
Net Investing Cash Flow	-135	42	-145	-313	-766		
Net Financing Cash Flow	-85	-97	-420	-236	-201		
Free Cash Flow	677	677	677	677	677		
ROA (%)	2.74	7.27	7.48	5.07	4.17		
ROE (%)	3.55	9.49	9.73	6.53	5.36		
EPS (Yen)	40.0	113.7	126.9	89.1	75.8		
BPS (Yen)	1,154.4	1,241.2	1,344.5	1,385.1	1,447.2		
Dividend per Share (Yen)	14.00	34.00	36.00	36.00	30.00	36.00	
Shares Outstanding (Million shrs)	6.05	6.05	6.05	6.05	6.05		

Source: Omega Investment from company data, rounded to the nearest whole number.

Share price






[Reposted] Key points in 'Towards cost of capital and share price conscious management'

^{人と科学のステキな未来へ} **コスモ・バイオ株式会社**



Executive Summary




[Reposted] Key points in 'Towards cost of capital and share price conscious management'

for normality for every dispersion of our west dispersion to the second se

人と科学のステキな未来へ コスモ・バイオ株式会社


^{人と科学のステキな未来へ} **コスモ・バイオ株式会社**




Source: Omega Investment from company materials



Examples tan nary Analysis of sevent structure to television to experience sevence of the sevenc




(Reposted) Key points in 'Towards cost of capital and share price conscious management'




Cosmo Bio (3386) | 2024/12/12

[Reposted] Key points in 'Towards cost of capital and share price conscious management'



Global Veterinary Drugs Market Research Report 2024-2036, Global Functional Foods Market 2023-2030, Functional Cosmetics Market: by Function, by Application - Global Forecast 2024-2030. Adapted from "Global Biopharmaceutical Market Research Report 2024-2036"

[Reposted] Key points in 'Towards cost of capital and share price conscious management'



Financial data (quarterly basis)

Unit: million yen	2022/12			202		2024/12			
	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q
(Income Statement)									
Sales	2,016	2,426	2,828	1,999	2,050	2,463	2,943	2,186	2,280
Year-on-year	-1.5%	3.2%	-7.2%	-3.1%	1.7%	1.5%	4.1%	9.4%	11.2%
Cost of Goods Sold (COGS)	1,305	1,576	1,789	1,273	1,350	1,678	1,956	1,460	1,522
Gross Income	711	850	1,039	726	700	785	987	726	758
Gross Income Margin	35.3%	35.0%	36.7%	36.3%	34.1%	31.9%	33.5%	33.2%	33.2%
SG&A Expense	635	736	638	668	711	712	681	708	713
EBIT (Operating Income)	76	114	401	58	-11	73	306	18	45
Year-on-year	-57.5%	-26.0%	-30.9%	23.4%	-114.5%	-36.0%	-23.7%	-69.0%	-509.1%
Operating Income Margin	3.8%	4.7%	14.2%	2.9%	-0.5%	3.0%	10.4%	0.8%	2.0%
EBITDA	112	153	435	94	28	112	336	50	79
Pretax Income	70	100	416	136	2	99	353	37	48
Consolidated Net Income	51	76	279	98	1	83	240	27	34
Minority Interest	5	13	15	1	-5	8	10	-2	2
Net Income ATOP	47	63	264	97	5	76	230	28	33
Year-on-year	-62.4%	-48.4%	-27.9%	136.6%	-89.4%	20.6%	-12.9%	-71.1%	560.0%
Net Income Margin	2.3%	2.6%	9.3%	4.9%	0.2%	3.1%	7.8%	1.3%	1.4%
(Balance Sheet)									
Cash & Short-Term Investments	3,347	3,036	3,026	3,852	3,637	3,025	2,813	3,224	3,044
Total assets	10,098	10,313	10,695	10,852	10,773	10,872	11,594	11,739	11,333
Total Debt	136	27	183	228	219	25	316	418	370
Net Debt	-3,211	-3,009	-2,843	-3,624	-3,418	-3,000	-2,497	-2,806	-2,674
Total liabilities	1,565	1,693	1,865	1,762	1,772	1,844	2,101	1,953	1,853
Total Sharehjolders' Equity	7,979	8,052	8,250	8,509	8,426	8,445	8,903	9,197	8,889
(Profitability %)									
ROA	5.79	5.07	3.91	4.44	4.12	4.17	3.66	3.01	3.31
ROE	7.34	6.53	5.13	5.69	5.24	5.36	4.76	3.84	4.23
(Per-share) Unit: JPY									
EPS	8.1	10.8	45.4	16.6	0.9	13.0	39.4	4.8	5.7
BPS	1,372.3	1,385.1	1,419.2	1,458.0	1,443.9	1,447.2	1,525.8	1,569.7	1,532.0
Dividend per Share	36.00	36.00	36.00	36.00	36.00	30.00	30.00	30.00	30.00
Shares Outstanding (million shrs)	6.05	6.05	6.05	6.05	6.05	6.05	6.05	6.05	6.05

Financial data (full-year basis)

Unit: million yen	2014/12	2015/12	2016/12	2017/12	2018/12	2019/12	2020/12	2021/12	2022/12	2023/12
(Income Statement)										
Sales	7,235	7,357	7,427	7,068	7,261	7,590	8,092	9,231	9,553	9,340
Year-on-year	2.6%	1.7%	1.0%	-4.8%	2.7%	4.5%	6.6%	14.1%	3.5%	-2.2%
Cost of Goods Sold	4,811	4,976	4,655	4,535	4,607	4,710	4,940	5,572	6,112	6,090
Gross Income	2,424	2,381	2,772	2,533	2,654	2,880	3,152	3,659	3,441	3,250
Gross Income Margin	33.5%	32.4%	37.3%	35.8%	36.6%	37.9%	39.0%	39.6%	36.0%	34.8%
SG&A Expense	2,262	2,181	2,257	2,339	2,330	2,474	2,399	2,609	2,624	2,729
EBIT (Operating Income)	162	200	515	194	324	406	753	1,050	817	521
Year-on-year	-40.2%	23.5%	157.5%	-62.3%	67.0%	25.3%	85.5%	39.4%	-22.2%	-36.2%
Operating Income Margin	2.2%	2.7%	6.9%	2.7%	4.5%	5.3%	9.3%	11.4%	8.6%	5.6%
EBITDA	248	279	600	350	507	613	928	1,216	958	669
Pretax Income	330	407	456	400	403	388	1,008	1,099	790	653
Consolidated Net Income	200	249	276	250	278	246	701	768	552	461
Minority Interest	-1	19	22	12	17	8	27	31	35	19
Net Income ATOP	201	230	254	237	260	237	674	737	517	442
Year-on-year	-35.8%	14.4%	10.4%	-6.7%	9.7%	-8.8%	184.4%	9.3%	-29.9%	-14.5%
Net Income Margin	2.8%	3.1%	3.4%	3.4%	3.6%	3.1%	8.3%	8.0%	5.4%	4.7%
(Balance Sheet)										
Cash & Short-Term Investments	1,482	1,498	1,948	1,483	2,268	2,516	3,259	3,555	3,036	3,025
Total assets	8,161	7,790	7,934	8,126	8,485	8,890	9,640	10,072	10,313	10,872
Total Debt	20	20	20	20	20	20	20	28	27	25
Net Debt	-1,462	-1,478	-1,928	-1,463	-2,248	-2,496	-3,239	-3,527	-3,009	-3,000
Total liabilities	1,629	1,412	1,350	1,286	1,430	1,566	1,776	1,750	1,693	1,844
Total Sharehjolders' Equity	6,050	5,951	6,135	6,381	6,581	6,843	7,358	7,787	8,052	8,445
(Cash Flow)										
Net Operating Cash Flow	297	129	573	294	909	569	803	648	306	744
Capital Expenditure	70	175	252	546	152	182	76	156	119	120
Net Investing Cash Flow	-227	-263	99	-440	-186	-135	42	-145	-313	-766
Net Financing Cash Flow	-122	-151	-107	-109	-85	-85	-97	-420	-236	-201
Free Cash Flow	244	80	444	-185	858	428	767	617	251	677
(Profitability %)										
ROA	2.45	2.88	3.23	2.96	3.14	2.74	7.27	7.48	5.07	4.17
ROE	3.25	3.83	4.20	3.80	4.03	3.55	9.49	9.73	6.53	5.36
(Per-share) Unit: JPY										
EPS	33.9	38.8	42.8	40.0	43.9	40.0	113.7	126.9	89.1	75.8
BPS	1,020.6	1,003.9	1,034.9	1,076.4	1,110.2	1,154.4	1,241.2	1,344.5	1,385.1	1,447.2
Dividend per Share	20.00	16.00	18.00	14.00	14.00	14.00	34.00	36.00	36.00	30.00
Shares Outstanding (million shrs)	6.05	6.05	6.05	6.05	6.05	6.05	6.05	6.05	6.05	6.05



General disclaimer and copyright

This report was created and displayed based on interviews with the company concerned and financial statements, but we do not guarantee the accuracy, completeness, or credibility of the content and data. This report is for informational purposes only and is not intended to solicit or recommend investment. Omega Investment is not responsible for the consequences of using this report.

This report is informed by the target company through interviews with the target company, but the hypotheses, conclusions and all other content contained in this report are based on research by Omega Investment.

Intellectual ownership, including copyrights of the text and data, belongs to Omega Investment. Distribution, transfer, reproduction, transfer or other use constitutes copyright infringement of this report and is strictly prohibited.